A

Abdominal cavity endoscopic exploration, pioneers of
Christian Jacobeus, 5
George Kelling, 6
Heinz Kalk, 6
John Ruddock, 6
Michael J. Mack, Mark J. Krasna, 6
Swierenga J, 6

Abdominal dissection, esophageal cancer
antrum and fundus, division of, 130
diagnostic laparoscopy and decision, 129
dissection
left gastric artery and vein, 130
retrogastric dissection, 129
feeding jejunostomy, placing of, 131–132
gastric conduit, creation of, 130
mobilization
gastric antrum, 129–130
gastric fundus, 129
greater curvature, 129
operating room set-up and trocar placement, 129
patient positioning and on-table endoscopy, 128
pyloroplasty–Heinecke-Mikulicz, 131

Abdominal tumors, pediatric, 502–503

Abdominoperineal resection
anal opening, closure of, 244
IMA, 245
IMV, 245
left colon
mobilization of, 245
proximal division, 245–246
operating field, exposure, 245
pelvic wound closure, 246
perineal dissection and specimen exteriorization, 246
positioning, patient and equipment, 244–245
rectum, mobilization of, 245
trocar placement positioning, 244–245
trocar sites and colostomy creation, 246
ADEPT. See Advanced Dundee Endoscopic Psychomotor
Tester (ADEPT)

Adjuvant/neo-adjuvant therapy, 102
Adjuvant therapy, 103
Adrenal gland cancer
adrenal incidentaloma
catecholamine hypersecretion, 392
follow-up metabolic testing, 392
general considerations, 391–392
hyperaldosteronism, 392
hypercortisolism, 392
adrenal surgery, clinical indications
Cushing’s syndrome, 390–391
functional adrenal mass, 390
isolated adrenal metastasis, 390, 391
suspected malignancy, 389–390
laparoscopic adrenalectomy, 393
perioperative considerations, 392–393
radiologic findings, 390
surgical anatomy, 395
surgical technique
advantages and disadvantages, 394
anterior transabdominal adrenalectomy, 395, 400–401
lateral transabdominal adrenalectomy, 394, 396–400
retroperitoneal adrenalectomy, 394–395, 401
Adrenal metastasis, 390, 391
Advanced Dundee Endoscopic Psychomotor
Tester (ADEPT), 17
Aging patient, minimally invasive surgery
adjuvant therapy role, 103
epidemiology, cancer, 97–98
minimally invasive management
colorectal cancer, 101
esophageal cancer, 100–101
gastric cancer, 101
lung cancer, 100
pathophysiological changes
cardiovascular, 98
derocrine, 99
gastrointestinal, 99
immunological, 99
musculoskeletal, 99
neurological, 99–100
pulmonary, 98
renal, 98–99
surgical approach
intraoperative management, 102–103
postoperative management, 103
preoperative management, 101–102
Anaplastic thyroid cancer, 334, 338
Anatomical liver resections
hepatectomies
classification, 284
surgical technique, 284–294
intra-operative ultrasound
objectives, 281
role, 275–276
technique and major steps, 281–282
laparoscopic liver surgery, 276–278
laparoscopic resections
indications, 273–274
liver transplants, role in, 274–275
vs. open approach, 274
primary liver tumors and HCC, 274
vs. radiofrequency ablation, 275
leak test, 283–284
minimally invasive liver surgery, 275
parenchyma dissection
CUSA® system, 282
EnSeal®, 283
Harmonic Scalpel® and Sonosurg®, 282
Ligasure®, 282
parameters, 282
personal technique, 283
stapling devices, 283
TissueLink™, 283
specimen removal, 283
surgical approach
anesthesia, special considerations, 280–281
operating room setup and equipment, 278–280
patient positioning, 280
preoperative evaluation, 278
trocar placement, 280, 281
Anterior transabdominal adrenalectomy (ATA)
adrenal gland dissection, 400–401
advantages and disadvantages, 394
difficulties in, 395
patient positioning and trocar placement, 400
Appendiceal malignancies
carcinoid tumors, 203–204
histological subtypes, 200–201
laparoscopy role, 202–203
mucinous neoplasm, 201–202
non mucinous tumor, 201
peritoneal carcinomatosis therapy, 202–203
Aromatic fatty acids, 338
Arterial angiography, 357
ATA. See Anterior transabdominal adrenalectomy (ATA)

B
BABA. See Bilateral axillary-breast approach (BABA)
Benign small bowel tumors, 187–188
Bilaterial axillary-breast approach (BABA), 346–347
Brachytherapy, prostate cancer, 468

C
Calcitonin, 333
Catecholamine blockade, 393
Catecholamine hypersecretion, 392
CD markers, 74–75
CD31 surface marker, 75
Cellular immunity
lymphocytes, 74–76
natural killer cell activity, 73–74
systemic monocyte function, 72–73
T-cell function, 71–72
Central hepatectomy, 288–289
Cervical cancer
advanced stage
interstitial radiation implant, 424
laparoscopic ovarian transposition, 424
pelvic and para-aortic lymphadenectomy, 423
pelvic exenteration, 424
early stage
laparoscopic lymphadenectomy, 417
radical vaginal hysterectomy, 415–416
robotic radical hysterectomy, 416–417
sentinel lymph node sampling, 417–421
total laparoscopic radical hysterectomy, 416
trachelectomy, 422–423
indications for laparoscopy, 407
surgical technique
general considerations and instruments, 408
laparoscopic radical hysterectomy, 408–412
lymphadenectomy, 413–415
Chemotherapy
Burkitts abdominal lymphoma, 503
gallbladder cancer, 300
parathyroid cancer, 360
Chronic lymphocytic leukemia (CLL), 315
Chronic myeloid leukemia (CML), 313, 316
CLL. See Chronic lymphocytic leukemia (CLL)
Clusters of differentiation, 74–75
CML. See Chronic myeloid leukemia (CML)
Colorectal cancer
aging patient, 101
laparoscopy, 63
Computed tomography (CT)
esophageal cancer staging, 128
pancreatic cancer, 363
parathyroid cancer, 357
Concurrent and construct validity, 14
Conn’s syndrome, 392
Content validity, 14
CO2 pneumoperitoneum, 77–78
Cryoablation
liver tumors, 29
prostate cancer
complications, 470
history and development, 469–470
method of action, 470
outcomes, 470–471
tumor tissue ablation, 29
CT. See Computed tomography (CT)
CUSA® system, 282
Cushing’s syndrome, 390–391
Cyberknife, 510, 524
Cyclin D1, 356
Cytokines, humoral immunity
C-reactive protein (CRP), 70
inflammatory cascade, 70
interleukin-1 (IL-1), 71
interleukin-6 (IL-6), 70–71
tumor necrosis factor alpha (TNF-α), 71

D
da Vinci oncological trends, 52
DaVinci™ robot, 459
Differentiated thyroid cancer (DTC)
anaplastic thyroid cancer, 338
follicular thyroid cancer
clinical presentation and prognosis, 337
FNA, 338
guidelines, 338
pathological features, 337
papillary thyroid cancer
early thyroidectomy, 336
features, 335
guidelines, 336–337
lobectomy vs. total thyroidectomy, 336
management, 337
Mount Sinai approach, 336
patient differentiation, 336
Disseminated peritoneal adenomucinosis (DPAM), 202
Distal pancreatectomy, 117
DPAM. See Disseminated peritoneal adenomucinosis (DPAM)
DTC. See Differentiated thyroid cancer (DTC)
Duodenojunostomy, 384

E
Early gastric cancer (EGC)
complications, 175
endoscopic resection (see Endoscopic resection)
outcomes, 178
postprocedure management, 175, 178
risk factors, 167
EBRT. See External beam radiotherapy (EBRT)
EGC. See Early gastric cancer (EGC)
Elderly patients. See Aging patient, minimally invasive surgery
EMR. See Endoscopic mucosal resection (EMR)
Endoluminal procedures, EGC
complications, 175
endoscopic resection
endoscopic submucosal dissection (ESD), 168
indications, 169–170
patient selection, 168–169
techniques, 170–177
outcomes, 178
postprocedure management, 176, 178
risk factors, 167
Endometrial cancer
conditions, 425
laparoscopic surgical staging, 426–427
patient positioning and technique, 425
quality of life assessment, 430
recurrence management, 428–429
robotic-assisted staging of, 427–428
special considerations
elderly, 430
obesity, 429–430
staging completion, 428–429
Endoscopic mucosal resection (EMR)
nonsuction technique—“lift-and-cut,” 170–171
suction technique—“suck-and-cut,” 171–173
Endoscopic resection
disseminated submucosal dissection (ESD), 168
indications
extended indications, 169–170
standard indications, 169
patient selection
endoscopic staging, 168
pathologic staging, 169
techniques
disseminated mucosal resection (EMR), 170–172
disseminated submucosal dissection (ESD), 172–177
Endoscopic staging
chromoendoscopy, 168
diagnostic ultrasound (EUS), 168
virtual gastroscopy, 168
Endoscopic submucosal dissection (ESD), 168, 172–177
Endoscopic thyroid surgery
non-cervical approach
BABA, 346–347
transaxillary approach, 347
oncological outcome, 344
patient selection, 344
rationale for, 343
risks and benefits, 343–344
transcervical approach
instrumentation, 345–346
operative steps, 346
patient positioning, 345
trocar configuration, 344
video-assisted thyroidectomy, 347–348
Endoscopic TV Vidicon tube camera, 9
Endoscopy
abdominal cavity, 5–6
definition and evolution, 3
illumination, 6–7
image transmission, 7–8
light source, 3–4
light source, Bozzini and Desormeaux, 3–4
open tube, 4
telescope, 4–5
television image, 8–10
EnSeal® vessel fusion system, 283
ENT, robotic applications, 53–54
ESD. See Endoscopic submucosal dissection (ESD)
Esophageal cancer
aging patient, 100–101
laparoscopy role, 126
nonsurgical management, 127
staging of, 128
surgical management
abdominal dissection, 128–132
esophagoanastomotic end-to-end anastomosis, 133–134
thoracic dissection, 132–133
Esophagogastric end-to-side anastomosis
drain placement and wound closure, 134
postoperative management, 134
two-cavity approach, 133–134
Esophagus and gastroesophageal junction
transhiatal approach
Barret’s dysplasia, 144
cervical anastomosis, 142
endoluminal treatment, 144
fundoplication, 142, 143
gastric conduit, 141–142
history, 138
minimal invasive esophagectomy, 137
postoperative management, 142–143
staging laparoscopy, 143, 144
suitable approach, 137–138
surgical management, 139–141
traditional open surgical approaches, 143
two-cavity approach
anatomy, 125
laparoscopy role, 126
minimally invasive techniques, 126–127
nonsurgical management, 127
postoperative management, 134
preoperative considerations, 128
resections, 125–126
staging, esophageal cancer, 128
surgical management, 128–134
External beam radiotherapy (EBRT)
gallbladder cancer, 300
prostate cancer
complications, 467
contraindications, 467–468
cytotoxicity, 466
planning strategies, 466
success and failure, 466–467
Extrahepatic bile duct cancer. See Gallbladder cancer

F
Face validity, 14
FDG-PET. See Fluorodeoxyglucose-positron emission tomography (FDG-PET)
Fine needle aspiration (FNA), 335
Flow cytometry, 357
Fluorodeoxyglucose-positron emission tomography (FDG-PET), 300
FNA. See Fine needle aspiration (FNA)
Follicular thyroid cancer, 337–338

G
Gallbladder cancer
controversies, surgical resection, 306
FOX CHASE data, 305
incidence of, 298
management
FDG-PET, 300
historical overview, 298
preoperative workup, 298, 300
staging and re-resection, 298, 299
non-surgical management of, 300
porcelain gallbladder, 298
risk factors, 297
surgical management of, 300–302
surgical procedures
hepatoduodenal lymphadenectomy, 302–304
laparoscopic common bile duct excision, 304–305
laparoscopic radical cholecystectomy, 302–304
laparoscopic Roux-en-Y choledocho-jejunostomy, 304–305
Gartner’s hype cycle of innovation, 40–41
Gastric cancer
aging patient, 101
laparoscopy, 62–63
Gastroesophageal junction. See Esophagus and gastroesophageal junction
Gastrointestinal stromal tumor (GIST), 186
Gastro-jejunal anastomosis
creation of, 155
techniques, 154–155
Genetic surgery, 42–43
GIST. See Gastrointestinal stromal tumor (GIST)
Global operative assessment of laparoscopic skills (GOALS), 17–18
Gynecological surgery, robotic applications, 53
Gynecologic malignancies
cervical carcinomas, laparoscopy and applications
advanced stage, 423–424
early stage, 415–423
indications for, 407
surgical technique, 408–415
endometrial cancer, laparoscopy and applications
conditions, 425
laparoscopic surgical staging, 426–427
patient positioning and technique, 425
quality of life assessment, 430
recurrence management, 429
robotic-assisted endometrial cancer staging, 427–428
special considerations, 429–430
staging completion, 428–429
fallopian tubal and primary peritoneal carcinomas, 430–438
ovarian cancer, laparoscopy and applications
advanced stage invasive, 434–437
borderline ovarian tumors, 432
early stage invasive, 432–434
laparoscopic management of, 438
management pitfalls, 437–438
surgical staging, 431
surgical technique, 431–432

H
Haemostasis, MIS
laser, 26
mechanical methods, 26
thermal methods, 26
tissue sealants, 26
Hand-assisted laparoscopic splenectomy (HALS)
indication for, 320
intermediate splenomegaly, 320–321
massive splenomegaly, 321
patient positioning, 320
specimen extraction, 322
splenectomy and, 325–326
splenic hilum, dissection of, 321–322
Hand-assisted laparoscopic surgery, 27–28, 269
Haptics, MIS, 33–34
Harmonic Scalpel®, 282
Hepatocutaneous
  central hepatectomy, 288–289
  classification, 284
  extended
    hepatectomy left, 289
    hepatectomy right, 289–290
  hemihepatectomies, 284–288
    major hepatectomy left, 286–288
    major hepatectomy right, 284–286
  limited hepatectomies-segmentectomies, 290–294
Hepaticojejunostomy, 384
Hepato-biliary system
  extrahepatic cholangiocarcinoma
    adjuvant therapy, 258
    advantages and disadvantages, 257
    classification, 256
    conventional surgical therapy, 256
    endoscopic diagnosis and unresectable disease
      palliation, 257
    endoscopic photodynamic therapy, 257–258
    epidemiology, 255
    pathology, 257
    preoperative workup, 256
    risk factors and symptoms, 256
    staging, 256–257
  gallbladder carcinoma
    epidemiology, 253
    preoperative workup, 253
    staging of, 253–254
    surgical therapy, 254
    symptoms, 253
  nonanatomical resection (See Liver, nonanatomical
    resection)
  operating room
    adjuvant therapy, 255
    intraoperative bile spillage problem, 254
    intraoperative positive frozen section management, 254
    laparoscopy and incidental, 254
    port site metastasis, 255
    staging, 255
  Hepatoblastoma, pediatric, 505
  Hepatoduodenal lymphadenectomy, 302–304.
    See also Laparoscopic radical cholecystectomy
  High-intensity focused ultrasound (HIFU), 28
    prostate cancer, 471–472
    tissue ablation, 28
  Hodgkin’s disease (HD), 315
  Hodgkin’s lymphoma (HL), 311–312
  Hopkins flexible fiber image transmission, 7
  Hopkins rod lens telescope, 8
  Human leukocyte antigen DR (HLA-DR), 72
  Humoral immunity, 70–71
  Hyperaldosteronism, 392
  Hypercortisolism, 392
I
  ICSAD. See Imperial College Surgical Assessment Device
    (ICSAD)
  Illumination, Heinrich Lamm, 6–7
IMA. See Inferior mesenteric artery (IMA)
  Image transmission, 7–8
Imperial College Surgical Assessment Device (ICSAD), 17
Inferior mesenteric artery (IMA)
    identification of, 224–225
    sigmoid branches, division, 225–226
  Intra-operative ultrasound
    anatomical liver resections
      objectives, 281
      role, 275–276
      technique and major steps, 281–282
  Intra-thoracic malignancies
    lung
      anatomic VATS lobectomy, left lung, 519–521
      anatomic VATS lobectomy, right lung, 515–519
      cancer, 523–524
      segmental resections, 522–523
      VATS lingular resection, 523
      VATS lingular sparing, 523
      wedge resection, 521–522
    mediastinum
      lymphatic tissue, 528
      pericardium, 526
      thymus, 526–527
      pleura, 525
  Iodine, 332
  13Iodine, 332
IPMN. See Pancreatic intraductal papillary
  mucinous neoplasm (IPMN)
Ivor Lewis esophagectomy, 126
J
  Japanese Society of Endoscopic Surgery (JSES), 163, 164
K
  Kidney cancer
    chemotherapeutic strategies, 447
    laparoscopic transperitoneal partial nephrectomy
      nephron sparing surgery, 456
      open to laparoscopic partial nephrectomy, 456
      transition, 456
      surgical technique, 456–457
    laparoscopic transperitoneal radical nephrectomy
      operating room set up and patient positioning, 450
      overview of, 450
      surgical technique, 451–454
      trocar placement, 450–451
    laparoscopy for, 448–450
    partial nephrectomy, 448, 449
    retro-peritoneoscopic partial nephrectomy
      indications, 457
      technical differences, 457–458
    retro-peritoneoscopic radical nephrectomy
      hilar vessels, dissection and accessing, 455
      indications and limitations, 454
      operating room setup and patient positioning, 454–455
      trocar placement, 455
      working space creation, 455
    robotic-assisted laparoscopic partial nephrectomy
      advantages, 458
      DaVinci™ robot, 459
parenchyma reconstruction, 460
patient positioning and trocar placement, 458–459
robotic dissection, 459–460
specimen removal and wound closure, 460
surgery, 447–448

L

LADG. See Laparoscopy-assisted distal gastrectomy (LADG)
Laparoscopic adrenalectomy, 393
Laparoscopic-assisted total gastrectomy (LATG) complications and technical difficulties
esophago-jejunostomy, reconstruction methods, 164–165
intra-and postoperative complications, 163, 165
evaluation, 165
gastro-splenic ligament
greater omentum, 161
indications, 159–160
irrigation, drainage, and wound closure, 163
Japanese Society of Endoscopic Surgery (JSES), 163, 164
surgical technique
Braun’s anastomosis, 163
duodenum transection, 162–163
esophago-jejunostomy, 163
esophagus transection, 162
greater omentum, 161
hepatic artery dissection, 162
irrigation, drainage, and wound closure, 163
left gastric vessels division, 162
lesser omentum and right gastric vessels division, 161–162
mini-laparotomy, 163
patient positioning, 160
posterior gastric artery division, 162–163
right gastro-epiploic vessels, 161
Roux-en-Y reconstruction, 163
trocar placement, 160
Laparoscopic cholecystectomy (LC), 11. See also Surgical residency training
Laparoscopic common bile duct excision, 304–305
Laparoscopic distal pancreatectomy fundamental categories, 365–366
multiple endocrine neoplasia (MEN), 367
patient selection, 366
preoperative tumor localization, 366
surgical technique, 367–371
Laparoscopic lymphadenectomy, cervical cancer, 417
Laparoscopic pancreaticoduodenectomy (LPD) challenges, 380
historic review, 380
patient outcomes, 385–387
patient positioning and trocar placement, 381
patient selection, 380–381
perioperative care, 384–385
reconstruction, 383–384
resection, 381–383
robotic-assisted approach, 386
training, 387
Laparoscopic radical cholecystectomy patient positioning and operating room setup, 303
postoperative detected gallbladder cancer, dissection for, 304
preoperative evaluation, 302
preoperative suspected gallbladder cancer, dissection for, 303–304
trocar placement, 303
Laparoscopic radical cystectomy anterior peritoneal incision, 490
apical dissection, 490
extended pelvic lymph node dissection, 491
general considerations, 488
indications, 488
operating room setup, 489
patient positioning, 489
port placement, 489
posterior peritoneal incision, 489
preoperative patient preparation, 489
ureters, identification and transection, 489–490
vascular pedicles, securing, 490
worldwide results, 492–494
Laparoscopic radical hysterectomy, cervical cancer adnexa, 410, 411
diagnostic laparoscopy, 408, 410
para-rectal space and uterine artery, 411
para-vesicle space, 411
recto-vaginal space, 411
ureters, identification and transection, 412
vaginal cuff closure, 412
vesico-vaginal space, 408, 410, 411
Laparoscopic radical prostatectomy contraindications, 473
evolution of, 473
indications, 473
postoperative management, 478
preoperative considerations, 474
technical steps
bladder mobilization and Retzius space, 475
bladder neck reconstruction, 477
deep dorsal venous complex, dissection of, 475–476
leak test, 477–478
neurovascular bundle, dissection of, 476–477
patient positioning, 474
prostate dissection and excision, 477
specimen extraction and wound closure, 478
trocar placement, 474
urethrovesical anastomosis, 477
vasa deferentia and seminal vesicles, dissection of, 475
Laparoscopic rectal procedures abdominoperineal resection anal opening, closure of, 244
IMA, 245
IMV, 245
left colon, mobilization of, 245
left colon, proximal division, 245–246
operating field, exposure, 245
pelvic wound closure, 246
perineal dissection and specimen exteriorization, 246
positioning, patient and equipment, 244–245
rectum, mobilization of, 245
trocar placement positioning, 244–245
trocar sites and colostomy creation, 246
laparoscopic Hartman’s procedure, 246
low anterior resection (LAR)
anastomosis, creation of, 243
IMA, 241
IMV, 241, 242
left colon and splenic flexure, mobilization, 242
operating field, exposure of, 241
pneumoperitoneum desufflation and trocar sites closure, 244
positioning, patient and equipment, 239–240
rectum, mobilization and division, 242, 243
surgical specimen, exteriorization of, 243
trocar placement, 240
minimally invasive palliative surgery, 246–247
preoperative staging and workup, 235–236
preoperative treatment, 236
surgical approach
laparoscopic loop ileostomy, 238
laparoscopic rectal resections, 239
laparoscopic surgery, rectal cancer, 238
preoperative planning and strategy, 238
surgical option
LAR vs. APR, 237
locally advanced tumors, surgery, 237
minimally invasive approaches, 237–238
resection margins, 237
transanal excision and transanal endoscopic microsurgery, 236
transanal intersphincteric mobilization, 244
Laparoscopic Roux-en-Y choledocho-jejunostomy, 304–305
Laparoscopic splenectomy (LS)
anticipatory and lateral approach, 319–320
complications
diaphragm perforation, 323
hemorrhage, 322–323
miscellaneous, 323
pancreatic tail injury, 323
essential equipment, 318
HALS, 320–322, 325–326
indications, 317
patient positioning, 319
preoperative workup and considerations, 318
Laparoscopic trachelectomy, cervical cancer, 422–423
Laparoscopic transperitoneal partial nephrectomy
nephron sparing surgery, 456
open to laparoscopic partial nephrectomy, transition, 456
surgical technique, 456–457
Laparoscopic transperitoneal radical nephrectomy
operating room set up and patient positioning, 450
overview of, 450
surgical technique
colon mobilization, 451
gonadal vein dissection, 451–452
hilum and renal vessels, dissection of, 452–453
kidney and adrenal gland mobilization, 453
renal vein tumor thrombi, 453
specimen extraction and wound closure, 454
ureter division, 453–454
trocar placement, 450–451
Laparoscopic urinary diversion
general considerations, 491–492
types, 491
Laparoscopy
elderly
adjuvant therapy, 103
epidemiology, aging and cancer, 97–98
minimally invasive management, 100–101
pathophysiological changes, 98–100
surgical approach, 101–103
esophageal cancer, 126
and immunology
anesthesia, 77
angiogenesis-related plasma protein changes, 78–79
cellular immunity, 71–76
CO2 pneumoperitoneum, 77–78
humoral immunity, 70–71
peritoneal immunity, 76–77
surgery and tumor resistance, 78
and malignancy
cancer–carcinomatosis, 60
cancer–curative intent, 59–60
cancer–palliation, 60
colorectal cancer, 63
gastric cancer, 62–63
immune system influence, 60–61
liver tumors, 63
pneumoperitoneum, 60
port-site metastasis, 61–62
staging, 63–64
moral and ethical issues
Gartner’s hype cycle of innovation, 40–41
intracellular surgery, 43
micro-robots, 43
OSATS, 40
robotic surgery, 41–42
surgeon and patient, dissociation of, 39
suspended animation, 44
tissue engineering and regeneration, 43–44
small bowel tumors (see Small bowel tumors)
theories, 61
Laparoscopy-assisted distal gastrectomy (LADG)
complications and technical difficulties, 163–165
diagnostic laparoscopy, step I, 151
dissection and division procedure, step II, 151–153
duodenum, division of, 152–153
gastro-jejunal anastomosis, step IV, 154–155
indications, 149
left gastric artery, step III, 154
lymph node dissection and Japanese classification, 149–150
results and complications, 155
sentinel lymph node mapping, 150
surgical technique
instruments, 150–151
patient positioning, 150
trocar placement, 151
LAR. See Low anterior resection (LAR)

Lateral transabdominal adrenalectomy (LTA)
advantages and disadvantages, 394
left side
adrenal gland dissection, 397–398
operating room setup and patient positioning, 396, 397
trocar placement, 396–397
right side
adrenal gland dissection, 399–400
patient positioning and trocar placement, 398–399

LATG. See Laparoscopic-assisted total gastrectomy (LATG)

Left hemicolectomy and sigmoid colon
complications and pitfalls
abdominal organs, puncture injuries of, 231
bleeding from abdominal wall, 230
port site metastasis, 230–231
trocar site hernias, 230
ureteral injuries, 231
operative technique
anastomosis, creation of, 243
colon, proximal division of, 228
instruments and equipment, 221
operative field, exposure of, 223–224
patient positioning, 221
preoperative considerations, 221
proximal mesorectum, dissection of, 228
rectum, distal division of, 228
sigmoid and descending colon, 226–227
splenic flexure, mobilization, 228–229
surgical specimen, extraction of, 229
team positioning, 221, 222
trocars, placement of, 222, 223
vascular approach, 224–226
wound closure, 230
SAGES and ASCRS, 219–220
surgical approach, 219, 221

Ligasure®, 282
Light transmission principles, 6
Liver, nonanatomical resection
complications, 265
HALS, 269
laparoscopic hepatectomies, 264
liver malignancies, 263–264
minimal invasive approach, 264
surgical technique
diagnostic laparoscopy and dissection line, 265, 267
dissection, operative steps, 267–268
operating room setup and patient positioning, 265, 266
specimen, 269
trocar placement, 265, 266
Liver tumors
cryoablation, 29
laparoscopy, 63
Lobectomy vs. total thyroidectomy, 336
Low anterior resection (LAR)
anastomosis, creation of, 243
IMA, 241
IMV, 241, 242
left colon and splenic flexure, mobilization, 242
operating field, exposure of, 241
pneumoperitoneum desufflation and trocar sites closure, 244
positioning, patient and equipment, 239–240
rectum, mobilization and division, 242, 243
surgical specimen, exteriorization of, 243
transanal intersphincteric mobilization, 244
trocar placement, 240
LPD. See Laparoscopic pancreaticoduodenectomy (LPD)
LS. See Laparoscopic splenectomy (LS)
Lung cancer
aging patient, 100
radiofrequency ablation (RFA), 523–524
robotic resection of, 54
stereotactic radiosurgery, 524
Lung tumors, pediatric
biopsy and metastasectomy, 507–508
osteosarcoma, pulmonary metastasectomy, 508
sub-centimeter pulmonary lesion, 508
thoracoscopic biopsy, 508–509
Lymphadenectomy, cervical cancer
para-aortic lymph node dissection, 413–414
pelvic lymphadenectomy, 413
retroperitoneal, 414–415
trocar placement, 413
Lymphatic tissue, 528
Lymph node dissection and Japanese classification, 149–150
Lymphocytes, 74

M
Malignancy
laparoscopy
cancer–carcinomatosis, 60
cancer–curative intent, 59–60
cancer–palliation, 60
colorectal cancer, 63
immune system influence, 60–61
liver tumors, 63
pneumoperitoneum, 60
port-site metastasis, 61–62
staging, 63–64
pneumoperitoneum (see Pneumoperitoneum)
Malignant cells
insufflation gas effect, 88–89
in vitro studies, 86–87
in vivo studies, 87–88
Malignant small bowel tumors, 184–186
Maryland virtual patient (MVP), 19–20
MCT. See Microwave coagulation therapy (MCT)
Mechanical/box trainers
limitations, 16
mechanical model, 14
MISTELS, 15
reliability and validation, 15
simulation training, 14–15
vs. virtual reality, 17
Mediastinal tumors
pediatric
biopsy and resection technique, 510
neuroblastoma, 509
robotic applications, 54
robotic thymectomy and resection, 54
Mediastinum, intra-thoracic malignancies
lymphatic tissue, 528
pericardium, 526
thymus, 526–527
Medullary thyroid cancer (MTC), 333
Metastatic tumors, 187
Micro-robots, laparoscopy, 43
Microwave coagulation therapy (MCT), 264
Minimally invasive open thyroidectomy (MIT)
definition, 341
Mount Sinai approach
instrumentation, 342
operative steps, 342
postoperative management, 343
regional anesthesia, 342
patient selection, 342
risks and benefits, 341
Minimally invasive surgery (MIS)
Cuschieri’s view, 23
device technology and research
HALS, 27–28
tissue ablation, 28–29
ergonomic and operating theatres technology, 34–35
haptics, 33–34
imaging technology and research
head-mounted display, 32
image-guided surgery, 30–31
image transmission, 29–30
light sources, 29
magnifying endoscopy, 31–32
instrument technology and research
haemostasis, 25–26
instrument development, 24–25
NOTES and instrument development, 26–27
problems, 24
tissue approximation and anastomosis, 25
robotics, 32–33
surgery without external scars, 35
telemedicine, 34
MISTELS, 15
MIT. See Minimally invasive open thyroidectomy (MIT)
Monocyte function
clinical research and animal research, 73
HLA-DR, 72
Morbid obesity, 207
Multiple endocrine neoplasia (MEN), 367
MVP. See Maryland virtual patient (MVP)
Myelofibrosis, 313, 315

N
Natural killer cell activity
animal research, 73–74
clinical research, 74
mechanism of action, 73
Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR), 108–109
Natural oriﬁce transluminal endoscopic surgery (NOTES)
animal models and human applications, 109–112
ethical issues, 42
gastro-jejunostomy, 115–116
intestinal resection, 118
lymph node biopsy, 115
and oncology, 109, 112
optimal access, 118–119
peritoneoscopy, 112–114
routine endoscopic procedures, 109–110
solid organ resection, 117–118
surgical procedures, 108
thoracoscopy and mediastinoscopy, 114–115
Nephrectomy, 117
Neuroblastoma, pediatric
biopsy, 504
resection, 504–505
surgical technique, 505
Non-Hodgkin’s lymphoma (NHL), 185–186, 312, 314
NOSCAR. See Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR)

NOTES. See Natural oriﬁce transluminal endoscopic surgery (NOTES)

O
Objective structured assessment of technical skills (OSATS), 15, 40
Oophorectomy, 117
Open radical prostatectomy
choice of approach, 472–473
history, 472
outcomes, 473
Open tube, Kussmaul, 4
OSATS. See Objective structured assessment of technical skills (OSATS)
Ovarian carcinomas
advanced stage invasive
clinical risk factors, 435
cyto-reductive surgery, 436–437
resectability determination, 435
second-look laparoscopy, 436
borderline ovarian tumors, 432
early stage invasive, 432–434
management algorithm, 438
management pitfalls
cyst rupture, 437
inadequate staging, 437
port-site metastases, 437–438
surgical staging, 431
surgical technique, 431–432
tumor, pediatric
laparoscopic access, 506–507
management of, 506

P
PACE. See Preoperative assessment of cancer in the elderly (PACE)
Pancreatic cancer
complications and recovery, 374, 376
interventional laparoscopy
central pancreatectomy, 368
enucleation, 369, 372–373
laparoscopic distal pancreatectomy, 365–371
splenic preservation, 370
laparoscopic resection
  neuroendocrine lesions, 371, 374
pancreatic cystic lesions, 374
laparoscopic staging of
  accuracy, 364
  context-dependent approach, 363
  criticisms, 365
  disease deemed resectable, 364
  efficacy, 364–365
  historical perspective, 363
  patient selection, 365
  unresectable disease, 364
patient study, 374, 375
whipple procedure
  adjuvant/neoadjuvant therapy, 379
  evolution of, 380
  IPMN, 380
  minimally invasive approach, 380–381
  patient outcomes, 385–387
  robotic whipple, 386
  surgical technique, 381–385
  training, 387
  vascular resection, 379
Pancreatic cystic lesions, 374
Pancreatic intraductal papillary mucinous neoplasm (IPMN), 380
Pancreatectomy, 383–384
Pancreatic tail injury, 323
Papillary thyroid cancer, 335–337
Para-aortic lymph node dissection, 413–414
Parathyroid adenoma (PRAD1), 356
Parathyroid cancer
  clinical features and laboratory findings, 356
  diagnostic modalities, 357
  etiology and risk factors, 355
  histology, 356–357
  hypercalcemia, 360
  incidence of, 355
  molecular pathogenesis, 356
  nonfunctioning carcinoma, 360
  outcome and prognosis, 361
  surgical treatment
    en bloc resection, 359
    intraoperative findings, 358
    operative strategy, 358–359
    postoperative surveillance, 359
    recurrent and metastatic parathyroid cancer, 359
    role of, 358
  systemic therapy, 360
  TNM staging, 357–358
Parenchyma dissection, liver resections
  CUSA® system, 282
  EnSeal®, 283
  Harmonic Scalpel® and Sonosurg®, 282
  Ligasure®, 282
  parameters, 282
  personal technique, 283
  stapling devices, 283
  TissueLink™, 283
Partial hysterectomy, 117
PECAM1, 75
Pediatric malignancies
  Cyberknife, 510
  intra-abdominal malignancies
    hepatoblastoma, 505
    neuroblastoma, 504–505
    ovarian mass, 506–507
    sacro-coccygeal teratoma, 506
    Wilms’ tumor, 503–504
  minimally invasive surgery (MIS)
    abdominal and pelvic tumors, 502–503
    benefits, in oncology, 502
    overview, 501–502
  thoracic malignancies
    lung tumors, 507–509
    mediastinal tumors, 509–510
    video-assisted thoracoscopic for, 507
Pelvic lymphadenectomy, 413
Pelvic tumors, pediatric, 502–503
Pericardium, 526
Peritoneal immunity, 76–77
Peritoneal mucinous carcinomatosis (PMCA), 202
Physiologic changes, whole patient
  Pleura, 525
  Pleurodesis, 525
Porcelain gallbladder, 298
Portal vein thrombosis, 326
PORTLAND approach
  esophagectomy, stage II
    mobilization, curvature, 140–141
    patient positioning and trocar placement, 140
  staging laparoscopy, stage I
    laparoscopic feeding jejunostomy, 140
    left gastric artery, lymphadenectomy and division, 139–140
    patient positioning and trocar placement, 139
Port-site recurrence
  clinical studies, 91–92
  laboratory studies
    abdominal wall trauma, 90
    aerosolization, tumor cells, 90

Pneumoperitoneum, 60
  insufflation gas effect, 88–89
  malignant cells
    in vitro studies, 86–87
    in vivo studies, 87–88
  physiologic changes, whole patient
    cardiac effects, 85–86
    central nervous system, 85
    deep venous thrombosis, 84
    hypercoagulability, 84
    pulmonary effects, 86
    pulmonary embolism, 84
    systemic immunity, 84–85
    visceral effects, 86
  port-site recurrence
    clinical studies, 91–92
    laboratory studies, 90–91
    prevention, 92–93
  tumor cells, 89–90
Porcelain gallbladder, 298
Physiologic changes, whole patient
  Pleura, 525
  Pleurodesis, 525
Pneumoperitoneum, 60
  insufflation gas effect, 88–89
  malignant cells
    in vitro studies, 86–87
    in vivo studies, 87–88
  physiologic changes, whole patient
    cardiac effects, 85–86
    central nervous system, 85
    deep venous thrombosis, 84
    hypercoagulability, 84
    pulmonary effects, 86
    pulmonary embolism, 84
    systemic immunity, 84–85
    visceral effects, 86
  port-site recurrence
    clinical studies, 91–92
    laboratory studies, 90–91
    prevention, 92–93
  tumor cells, 89–90
Porcelain gallbladder, 298
Physiologic changes, whole patient
  Pleura, 525
  Pleurodesis, 525
Pneumoperitoneum, 60
  insufflation gas effect, 88–89
  malignant cells
    in vitro studies, 86–87
    in vivo studies, 87–88
  physiologic changes, whole patient
    cardiac effects, 85–86
    central nervous system, 85
    deep venous thrombosis, 84
    hypercoagulability, 84
    pulmonary effects, 86
    pulmonary embolism, 84
    systemic immunity, 84–85
    visceral effects, 86
  port-site recurrence
    clinical studies, 91–92
    laboratory studies, 90–91
    prevention, 92–93
  tumor cells, 89–90
Porcelain gallbladder, 298
Physiologic changes, whole patient
  Pleura, 525
  Pleurodesis, 525
Pneumoperitoneum, 60
  insufflation gas effect, 88–89
  malignant cells
    in vitro studies, 86–87
    in vivo studies, 87–88
  physiologic changes, whole patient
    cardiac effects, 85–86
    central nervous system, 85
    deep venous thrombosis, 84
    hypercoagulability, 84
    pulmonary effects, 86
    pulmonary embolism, 84
    systemic immunity, 84–85
    visceral effects, 86
  port-site recurrence
    clinical studies, 91–92
    laboratory studies, 90–91
    prevention, 92–93
  tumor cells, 89–90
Porcelain gallbladder, 298
Physiologic changes, whole patient
  Pleura, 525
  Pleurodesis, 525
Pneumoperitoneum, 60
  insufflation gas effect, 88–89
  malignant cells
    in vitro studies, 86–87
    in vivo studies, 87–88
  physiologic changes, whole patient
    cardiac effects, 85–86
    central nervous system, 85
    deep venous thrombosis, 84
    hypercoagulability, 84
    pulmonary effects, 86
    pulmonary embolism, 84
    systemic immunity, 84–85
    visceral effects, 86
  port-site recurrence
    clinical studies, 91–92
    laboratory studies, 90–91
    prevention, 92–93
  tumor cells, 89–90
immunosuppression theory, 91
port composition, 91
port placement, 91
wound closure type, 90–91
prevention, 92–93
Preoperative assessment of cancer in the elderly (PACE), 101–102
Prostate cancer
brachytherapy, 468
cryoablation
complications, 470
history and development, 469–470
method of action, 470
outcomes, 470–471
external beam radiotherapy (EBRT)
complications, 467
contraindications, 467–468
cytotoxicity, 466
planning strategies, 466
success and failure, 466–467
high-intensity focused ultrasound (HIFU), 471–472
laparoscopic radical prostatectomy
contraindications, 473
evolution of, 473
indications, 473
postoperative management, 478
preoperative considerations, 474
technical steps, 474–478
nonsurgical management, 465–466
open radical prostatectomy
choice of approach, 472–473
history, 472
outcomes, 473
patient outcomes
biochemical progression, 481
complication rates, 480
laparoscopic vs. robotic and open procedures, 479–480
procedure-associated morbidity, 480
sexual function, 481
urinary continence, 481
robotic radical prostatectomy, 478
stereotactic hypo-fractionated radiosurgery, 468–469
Proteomics and structural genomics, 49
Pseudomyxoma peritonei (PMP), 202

R
Radiation therapy
gallbladder cancer, 300
parathyroid cancer, 360
urinary bladder cancer, 487
Radical nephrectomy, pediatric, 504
Radical vaginal hysterectomy
Schauta–Amreich, 415–416
Schauta–Stoeckel, 416
Radioactive iodine (RAI), 331
Radiofrequency ablation (RFA), 28, 264
hepatocellular carcinoma, 275
liver malignancies, 264
lung cancer, 523–524
tissue ablation, 28
REA. See Retroperitoneal adrenalectomy (REA)
Retinoid therapy, 338
Retrogastric dissection, esophageal cancer, 129–132
Retroperitoneal adrenalectomy (REA)
advantages and disadvantages, 394–395
surgical technique, 401
Retroperitoneal lymphadenectomy, 414–415
Retro-peritoneoscopic partial nephrectomy, 457–458
Retro-peritoneoscopic radical nephrectomy
hilar vessels, dissection and accessing, 455
indications and limitations, 454
operating room setup and patient positioning, 454–455
trocar placement, 455
working space creation, 455
Reverse transcription polymerase chain reaction (RT-PCR), 335
RFA. See Radiofrequency ablation (RFA)
Right hemicolectomy and appendix
appendiceal malignancies
carcinoid tumors, 203–204
histological subtypes, 200–201
laparoscopy role, 202–203
mucinous neoplasm, 201–202
non mucinous tumor, 201
peritoneal carcinomatosis therapy, 202–203
colorectal cancer, factors associated with
after cholecystectomy, 199–200
hyperplastic polyps, 200
serrated adenoma, 200
complications, 213, 214
eliminating skin incisions/surgery with no scars, 214
laparoscopic right hemicolectomy
patient positioning and operating room setup, 209
pre-operative and intra-operative, tumor
localization, 208
preoperative preparation, 208
surgical steps, 208, 210–213
trocar placement, 209–210
mini laparoscopy, 214
postoperative care, 213
right colon cancer treatment
non surgical therapies, 205
surgical treatment, 205–208
single-port endoscopic surgery, 214
Robot-assisted laparoscopic cystectomy, 494–495
Robotic applications
artificial intelligence, 48
cancer cells, automated identification of, 48–49
da Vinci oncolgic trends, 52
dynamic active constraints and haptics, 50
general surgery, 55
clinical abnormalities, 48
gynecological surgery, 53
MIS, 32–33
oncologic predictive algorithms, 47–48
overlay, arterial targets, 51
proteomics and structural genomics, 49
registration difficulties, 50
robotic brachytherapy, 52
robotic stereotactic radio-surgery, 51–52
robotic surgery, 41–42
Index

skull base surgery and ENT, 53–54
thoracic surgery, 54
tumor localization, 49–50
tumor tracking and motion compensation, 51
urology
renal cancer, robotic resection of, 53
robotic prostatectomy, 52–53
Robotic-assisted laparoscopic partial nephrectomy
advantages, 458
DaVinci™ robot, 459
parenchyma reconstruction, 460
patient positioning and trocar placement, 458–459
robotic dissection, 459–460
specimen removal and wound closure, 460
Robotic esophageal resection, 54
Robotic gastric surgery, 54–55
Robotic large bowel procedures, 55
Robotic radical hysterecetomy, 416–417
Robotic radical prostatectomy, 478
Robotic resection
esophageal resection, 54
lung cancer, 54
mediastinal tumors, 54
renal cancer, 53
solid organ lesions, 55
Robotic thymectomy, 54
Robotic whipple, 386
S
Sacro-coccygeal teratoma (SCT), 506
Salpingectomy, 117
Sentinel lymph node mapping, 150
Sentinel lymph node sampling, 417–421
Single port access (SPA), 42
Skull base surgery, robotic applications, 53–54
Small bowel tumors
benign small bowel tumors
hamartoma, 187–188
hemangioma, 188
leiomyoma, 187
lipoma, 188
small bowel adenoma, 187
diagnostic work-up, endoscopic evaluation
balloon-assisted endoscopy, 189
capsule endoscopy, 188–189
intraoperative enteroscopy, 189
push enteroscopy and overtubes, 188
epidemiology, 183–184
malignant small bowel tumors
adenocarcinoma, 184–185
carcinoid tumor, 185
GIST, 186
metastatic tumors, 187
non-Hodgkin’s lymphoma (NHL), 185–186
postoperative management and outcome, 194
preoperative management
anastomosis, creation of, 192–193
contraindications, 190
diagnostic laparoscopy, 192
dissection and transection, 192
hand-assisted approach, 193
indications, 189–190
patient positioning, 191
preoperative considerations, 190–191
preoperative localization, 190
specimen and wound closure, 194
trocar placement, 191
tumor size, relevance of, 190
Solid organ lesions, robotic resection of, 55
Sonosurg®, 282
Spleen, hematological disorders
Barcelona data
CLL, 315
CML, 316
diagnostic laparoscopy, 316–317
Hodgkin’s disease, 315
myelofibrosis, 315
NHL, 314
perioperative outcome after LS, 315
primary and secondary splenic lymphoma, 314
secondary tumors, 316, 317
Waldenström’s macroglobulinemia, 316
classification and current nonsurgical therapies
chronic myeloid leukemia, 313
Hodgkin’s lymphoma, 311–312
myelofibrosis, 313
non-Hodgkin’s lymphoma, 312
laparoscopic splenectomy, 311
laparoscopic splenectomy, complications
diaphragm perforation, 323
hemorrhage, 322–323
pancreatic tail injury, 323
massive splenomegaly, 324
MIS, 311
portal vein thrombosis, 326
preoperative splenic embolization, role of, 325
primary tumors, 313
secondary tumors, 313–314
splenectomy
HALS and, 325–326
malignancy and, 325
splenic vessels, 325
splenomegaly, 323–324
surgical technique
anterior approach, 319
essential equipment, 318
general considerations, 318–319
hand-assisted laparoscopic splenectomy, 320–322
laparoscopy staging, 322
lateral approach, 319–320
lymph node biopsy, 322
patient positioning, 319
preoperative imaging, 318
preoperative workup and special considerations, 318
SAE, 318
specimen extraction, 320
splenectomy, 317
Splenectomy, 117
Splenic artery embolization (SAE), 318
Splenomegaly
massive, 324
spleen weight, 323–324
Stereotactic radiosurgery
  lung cancer, 524
  prostate cancer, 468–469
Surgical residency training
  cognitive skills, 19–20
  cost considerations, 18–19
  fellowship council, 12–13
  laparoscopic training, 12, 20
  objective metrics, 17
  proctoring and preceptoring, 12
  resident education guidelines, 13
simulation training
  box trainers, limitations of, 16
  broad categories, 13–14
  GOALS, 17–18
  mechanical/box trainers, 14–16
  MISTELS, 15
  reliability and validation, 14
  virtual reality, limitations and challenge, 16–17
  transfer of training, 18
  value and relevance, 19
  work-hour restrictions, 18

T-cell function
  animal research, 72
  clinical research, 72
  delayed type hypersensitivity (DTH), 71–72
  significance, 72
Telescope, pioneers of
  Fritz Lange and C.A. Meltzing, 5
  Galileo Galilei, 4
  Johann Mikulicz, 4–5
  Maximilian Frederick Nitze, 4–5
  Theodor Rosenheim and Rudolf Schindler, 5
Telesurgery technology
  MIS, 34
Television bronchoscopy, 9
Television image, 8–10
T-helper 1 and T-helper 2, 75
Thoracic dissection, esophageal cancer
  diaphragm, retraction of, 132
  dissection
    azigos vein, 133
    conduit and completion, 133
    lateral dissection and thoracic duct, 133
    operating room set-up and trocar placement, 132
    subcarinal node package, 132–133
Thoracic surgery, robotic applications, 54
Thymus, 526–527
Thyroglobulin (Tg), 333
Thyroid cancer
  differentiated, management of
    anaplastic thyroid cancer, 338
    follicular thyroid cancer, 337–338
    papillary thyroid cancer, 335–337
  minimally invasive approaches
    adjunctive techniques and equipment, 340–341
    endoscopic thyroid surgery, 343–348
    general considerations, 338–339
    minimally invasive open technique, 341–343
  patient selection, 339–340
  risks and benefits, 339
  video-assisted lateral neck dissection, 348
  palpable thyroid mass
    definition, risk factors and clinical presentation, 334
    fine needle aspiration, 335
    hot and cold nodules, 334
    molecular testing, 335
    ultrasound evaluation, 334
  pathology
    anaplastic thyroid cancer, 334
    differentiated thyroid cancers, 333
    medullary thyroid cancer, 333
  physiology
    calcitonin, 333
    iodine and 131iodine, roles, 332
    para-follicular C cells, 332
    thyroglobulin, 333
    thyroid hormones – T3/T4, 332
    thyroid stimulating hormone, 332
    radioactive iodine, 331
    recurrence rate, 331
  Thyroid stimulating hormone (TSH), 332
  Thyroxine (T4), 332
Tissue ablation
  cryoablation, 28–29
  HIFU, 28
  microwave ablation, 28–29
  RFA, 28
Tissue engineering and regeneration, 43–44
TissueLink™ device, 283
Total laparoscopic radical hysterectomy, 416
Transhiatal approach
  Barret’s dysplasia, 144
  endoluminal treatment, 144
  esophageal cancer, surgical management
    esophagectomy, stage II, 140–141
    staging laparoscopy, stage I, 139–140
  esophageal resection, 137–138
  fundoplication, 142, 143
  gastric conduit
    creation, 141–142
    pull up, 142
  history, 137–138
  minimal invasive esophagectomy, 137
  staging laparoscopy, 143–144
  traditional open surgical approaches, 143
Transhiatal esophagectomy, 125
Transluminal surgery
  minimally invasive techniques, 107
  NOSCAR, 108–109
NOTES
  animal models and human applications, 109–112
  gastro-jejunostomy, 115–116
  intestinal resection, 118
  lymph node biopsy, 115
  and oncology, 109, 112
  optimal access, 118–119
  peritoneoscopy, 112–114
  solid organ resection, 116–118
surgical procedures, 108
thoracoscopy and mediastinoscopy, 114–115
Transurethral resection of bladder (TUR-B), 487–488
Triiodothyronine (T3), 332
Tumor resistance, 78–79
Two-cavity approach. See Esophagus and gastroesophageal junction

U
Ultrasound
endoscopic, EGC resection, 168
esophageal cancer, 128
in liver surgery, 275–276
palpable thyroid mass, 334
parathyroid cancer, 357
prostate cancer, 471–472
tissue ablation, 28

Urinary bladder cancer
laparoscopic radical cystectomy
anterior peritoneal incision, 490
apical dissection, 490
extended pelvic lymph node dissection, 491
general considerations, 488
indications, 488
operating room setup, 489
patient positioning, 489
port placement, 489
posterior peritoneal incision, 489
preoperative patient preparation, 489
ureters, identification and transection, 489–490
vascular pedicles, securing, 490
worldwide results, 492–494

laparoscopic urinary diversion
general considerations, 491–492
types, 491

lap-assisted ileal conduit urinary diversion, 492
multimodality treatment, 488
radiation therapy, 487
robot-assisted laparoscopic cystectomy, 494–495
transurethral resection of bladder (TUR-B), 487–488

Urology, robotic applications
renal cancer, robotic resection of, 53
robotic prostatectomy, 52–53

V
Vascular approach, 224–226
Venography, 357
Video-assisted lateral neck dissection, 348
Video-assisted thoracic surgery (VATS) lobectomy
left lung
left lower lobectomy (LLL), 520–521
left upper lobectomy (LUL), 519–520
lingular resection, 523
lingular sparing, LUL, 523
right lung
right lower lobectomy (RLL), 519
right middle lobectomy (RML), 518
right upper lobectomy (RUL), 515–518
Video-assisted thoracic surgery (VATS) thymectomy, 527
Video-assisted thoracoscopy, 507
Video-assisted thyroidectomy, 347–348
Virtual reality (VR)
vs. box/mechanical trainers, 17
limitations and challenges, 16–17
simulators, 13–14, 16

W
Waldenstrom’s macroglobulinemia, 316
Wilms’ tumor, 503–504